Skip to Main Navigation Skip to the Content Skip to the Footer
Clinical Trials A031701

A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

A Clinical Trial for Bladder/Urothelial cancer in
  • Baton Rouge
  • Covington
  • Houma
.

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer.

Learn More